Haisco Pharmaceutical Group Co.,Ltd. (002653.SZ) announced that it has received a Drug Clinical Trial Approval Notice from the National Medical Products Administration. The review found that the HSK60002 tablet, accepted for filing in July 2026, meets the relevant requirements for drug registration, and the company has been granted approval to conduct clinical trials for this product.

HSK60002 is an oral small-molecule formulation independently developed by the company with its own intellectual property rights. It is intended for the treatment of inflammatory diseases. Preclinical study data indicate that HSK60002 has demonstrated significant pharmacodynamic activity and a clear mechanism of action in relevant animal models. Based on the current results, HSK60002 possesses clear development value and promising translational prospects, offering the potential to provide patients with an efficient and safe new therapeutic option.